Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2019 | 11:10am EDT

DGAP Voting Rights Announcement: MorphoSys AG
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

09.05.2019 / 17:05
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: MorphoSys AG
Street: Semmelweisstr. 7
Postal code: 82152
City: Planegg
Germany
Legal Entity Identifier (LEI): 529900493806K77LRE72

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Voluntary group notification with threshold triggered on advisor level

3. Details of person subject to the notification obligation
Legal entity: FMR LLC
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
07 May 2019

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 8.95 % 0.00 % 8.95 % 31,839,572
Previous notification 8.91 % 0.00 % 8.91 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0006632003 2,848,498 % 8.95 %
Total 2,848,498 8.95 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
FMR LLC % % %
Fidelity Management & Research Company 5.94 % % 5.94 %
 
FMR LLC % % %
FIAM Holdings LLC % % %
Fidelity Institutional Asset Management Trust Company % % %
 
FMR LLC % % %
FIAM Holdings LLC % % %
FIAM LLC % % %
 
FMR LLC % % %
Fidelity Advisory Holdings LLC % % %
Strategic Advisers LLC. % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
08 May 2019



09.05.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Internet: www.morphosys.com

 
End of News DGAP News Service

809265  09.05.2019 

fncls.ssp?fn=show_t_gif&application_id=809265&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
10:58aMORPHOSYS : Presents Primary Analysis Data from L-MIND Study of Tafasitamab in c..
AQ
06/22MORPHOSYS : Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR..
EQ
06/14MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/14MORPHOSYS : Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (..
EQ
06/11MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/05MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/03MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/24MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/24MORPHOSYS : to Present at Upcoming Investor Conferences
AQ
05/23MORPHOSYS : to Present at Upcoming Investor Conferences
EQ
More news
Financials (€)
Sales 2019 74,8 M
EBIT 2019 -92,3 M
Net income 2019 -99,6 M
Finance 2019 381 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 31,8x
EV / Sales 2020 22,0x
Capitalization 2 762 M
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 90,7 €
Spread / Average Target 4,5%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-2.47%3 040
IQVIA HOLDINGS INC36.58%26 223
LONZA GROUP28.86%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION39.49%17 061
EXACT SCIENCES CORPORATION83.26%13 037